Revisiting Antiangiogenic Multikinase Inhibitors in the Era of Immune Checkpoint Blockade: The Case of Sorafenib. Duda DG, Jain RK. Cancer Res 2022;82:3665-3667.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Duda DG, Jain RK. Revisiting Antiangiogenic Multikinase Inhibitors in the Era of Immune Checkpoint Blockade: The Case of Sorafenib. Cancer Res 2022;82:3665-3667.
PMID: 36245248